Eli Income Tax Expense vs Research Development Analysis
LLY Stock | USD 733.51 8.64 1.19% |
Eli Lilly financial indicator trend analysis is much more than just examining Eli Lilly latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eli Lilly is a good investment. Please check the relationship between Eli Lilly Income Tax Expense and its Research Development accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Income Tax Expense vs Research Development
Income Tax Expense vs Research Development Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eli Lilly Income Tax Expense account and Research Development. At this time, the significance of the direction appears to have very week relationship.
The correlation between Eli Lilly's Income Tax Expense and Research Development is 0.23. Overlapping area represents the amount of variation of Income Tax Expense that can explain the historical movement of Research Development in the same time period over historical financial statements of Eli Lilly and, assuming nothing else is changed. The correlation between historical values of Eli Lilly's Income Tax Expense and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Tax Expense of Eli Lilly and are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Income Tax Expense i.e., Eli Lilly's Income Tax Expense and Research Development go up and down completely randomly.
Correlation Coefficient | 0.23 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Income Tax Expense
Research Development
Most indicators from Eli Lilly's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eli Lilly current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, Eli Lilly's Discontinued Operations is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.32 in 2024, whereas Selling General Administrative is likely to drop slightly above 5.7 B in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 21.0B | 21.9B | 27.5B | 28.9B | Total Revenue | 28.3B | 28.5B | 34.1B | 35.8B |
Eli Lilly fundamental ratios Correlations
Click cells to compare fundamentals
Eli Lilly Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eli Lilly fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 39.3B | 46.6B | 48.8B | 49.5B | 64.0B | 67.2B | |
Short Long Term Debt Total | 15.8B | 16.6B | 16.9B | 16.2B | 25.2B | 26.5B | |
Total Current Liabilities | 11.8B | 12.5B | 15.1B | 17.1B | 27.3B | 28.7B | |
Total Stockholder Equity | 2.6B | 5.6B | 9.0B | 10.6B | 10.8B | 9.0B | |
Property Plant And Equipment Net | 8.4B | 8.7B | 9.0B | 10.1B | 12.9B | 6.8B | |
Net Debt | 13.5B | 12.9B | 13.1B | 14.2B | 22.4B | 23.5B | |
Retained Earnings | 4.9B | 7.8B | 9.0B | 10.0B | 10.3B | 9.5B | |
Cash | 2.3B | 3.7B | 3.8B | 2.1B | 2.8B | 3.1B | |
Non Current Assets Total | 25.6B | 29.2B | 30.4B | 31.5B | 38.3B | 40.2B | |
Non Currrent Assets Other | 2.3B | 3.5B | 4.1B | 4.3B | 5.0B | 2.9B | |
Cash And Short Term Investments | 2.4B | 3.7B | 3.9B | 2.2B | 2.9B | 3.7B | |
Net Receivables | 5.5B | 6.9B | 8.1B | 8.6B | 11.3B | 11.9B | |
Common Stock Shares Outstanding | 935.7M | 912.5M | 911.7M | 904.6M | 903.3M | 868.4M | |
Liabilities And Stockholders Equity | 39.3B | 46.6B | 48.8B | 49.5B | 64.0B | 67.2B | |
Non Current Liabilities Total | 24.8B | 28.3B | 24.6B | 21.6B | 25.8B | 27.1B | |
Inventory | 3.2B | 4.0B | 3.9B | 4.3B | 5.8B | 6.1B | |
Other Current Assets | 2.5B | 2.9B | 2.5B | 3.0B | 149.5M | 142.0M | |
Other Stockholder Equity | 3.6B | 3.7B | 3.8B | 3.9B | 4.2B | 2.3B | |
Total Liab | 36.6B | 40.8B | 39.7B | 38.7B | 53.1B | 55.8B | |
Total Current Assets | 13.7B | 17.5B | 18.5B | 18.0B | 25.7B | 27.0B | |
Intangible Assets | 6.6B | 7.5B | 7.7B | 7.2B | 6.9B | 7.3B | |
Other Current Liab | 2.2B | 2.8B | 3.0B | 13.7B | 3.3B | 3.7B | |
Short Term Debt | 1.5B | 8.7M | 1.5B | 1.5B | 6.9B | 7.2B | |
Accounts Payable | 1.4B | 1.6B | 1.7B | 1.9B | 2.6B | 2.7B | |
Property Plant And Equipment Gross | 8.4B | 8.7B | 19.0B | 20.4B | 24.0B | 25.2B | |
Accumulated Other Comprehensive Income | (6.5B) | (6.5B) | (4.3B) | (3.8B) | (4.3B) | (4.5B) | |
Common Stock Total Equity | 661M | 598.8M | 598.2M | 594.1M | 534.7M | 494.1M | |
Short Term Investments | 101M | 24.2M | 90.1M | 144.8M | 109.1M | 103.6M | |
Capital Stock | 598.8M | 598.2M | 596.3M | 594.1M | 593.6M | 544.7M | |
Common Stock | 598.8M | 598.2M | 596.3M | 594.1M | 593.6M | 544.7M | |
Other Liab | 10.5B | 11.0B | 8.7B | 6.1B | 7.0B | 5.5B | |
Other Assets | 4.7B | 9.3B | 6.4B | 7.1B | 8.2B | 4.2B | |
Long Term Debt | 13.8B | 16.6B | 15.3B | 14.7B | 18.3B | 19.2B | |
Treasury Stock | (60.8M) | (55.7M) | (52.7M) | (50.5M) | (44.2M) | (46.4M) | |
Property Plant Equipment | 7.9B | 8.7B | 9.0B | 10.1B | 11.7B | 8.5B | |
Good Will | 3.7B | 3.8B | 3.9B | 4.1B | 4.9B | 2.9B | |
Current Deferred Revenue | 6.7B | 8.1B | 8.8B | 14.5B | 16.7B | 17.5B | |
Noncontrolling Interest In Consolidated Entity | 92.2M | 183.6M | 175.6M | 125.6M | 91.8M | 141.7M | |
Retained Earnings Total Equity | 13.9B | 11.4B | 4.9B | 10.0B | 11.5B | 10.8B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.13 | Dividend Share 4.52 | Earnings Share 5.79 | Revenue Per Share 37.908 | Quarterly Revenue Growth 0.281 |
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.